The FDA granted orphan-drug status to Apocept, or APG101, Apogenix's investigational drug for myelodysplastic syndromes. The company said it launched an early-stage trial in Germany to assess Apocept's safety, efficacy and tolerability in MDS patients.
FDA gives orphan-drug designation to Apogenix's MDS drug Apocept
SmartBrief Job Listings for Health Care
|Director, Quality Assurance||
|Provider Relations Manager||
Breakthrough Behavioral, Inc.
|Redwood City, CA|
|Director Account Management||
Samaritan Health Services
|Hospital Medical Device Sales||
Linda Hertz Group